🧪 UPDATED DAILY FROM CLINICALTRIALS.GOVSynced Apr 1

Find Clinical Trials for Your Rare Disease

9550+ recruiting trials across all rare diseases. Filter by phase, location, and condition.

Clinical trial records are synced from ClinicalTrials.gov.
Report missing data

Showing 20 of 9550 recruiting trials

Phase 2RecruitingNCT07399704

A Study to Evaluate the Safety and Efficacy of Nizubaglustat (AZ-3102) in Patients With GM2 Gangliosidosis or Niemann-Pick Type C Disease

🏥 Azafaros A.G.📍 3 sites📅 Started Feb 2026View details ↗
Phase 1, PHASE2RecruitingNCT07471789

Safety and Efficacy of GYA01 (CART84) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Acute Lymphoblastic T Leukemia Patients (T-ALL).

🏥 Gyala Therapeutics📍 2 sites📅 Started Feb 2026View details ↗
EARLY_Phase 1RecruitingNCT07441525

UCAR-T Targeting CD19/BCMA in Subjects With Autoantibody-Mediated Autoimmune Benign Hematological Diseases

🏥 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology📍 1 site📅 Started Feb 2026View details ↗
RecruitingNCT07411690

Analysis of Cerebrospinal Fluid Leakage After Surgery for Intracranial Tumors

👨‍⚕️ Michal Senger, M.D., Department of Neurosurgery, Medical University of Warsaw, Warsaw, Poland📍 1 site📅 Started Feb 2026View details ↗
Phase 3RecruitingNCT07431281

Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

🏥 AstraZeneca📍 230 sites📅 Started Feb 2026View details ↗
Phase 1RecruitingNCT07480941

Dual-Targeting CAR-NK Cells for Recurrent/Progressive Glioblastoma and High-Grade Glioma

🏥 Beijing Biotech📍 1 site📅 Started Feb 2026View details ↗
Phase 1, PHASE2RecruitingNCT07480213

Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)

🏥 Beijing Biotech📍 1 site📅 Started Feb 2026View details ↗
Enrolling by InvitationNCT07347002

Observational Study to Assess the Effectiveness of VLA1553 Vaccine in Preventing Chikungunya During a Pilot Vaccination Strategy in Brazil

🏥 Valneva Austria GmbH📍 4 sites📅 Started Feb 2026View details ↗
Phase 4RecruitingNCT07247058

Isturisa Treatment in Mild Autonomous Cortisol Secretion( MACS)

👨‍⚕️ Amir Hamrahian, MD, Johns Hopkins University📍 1 site📅 Started Feb 2026View details ↗
Enrolling by InvitationNCT07254702

Prospective Safety Cohort Study After VLA1553 Vaccination in Municipalities Selected for Participation in the VLA1553 Pilot Vaccination Strategy in Brazil

🏥 Valneva Austria GmbH📍 4 sites📅 Started Feb 2026View details ↗
Phase 2RecruitingNCT07224360

Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD)

👨‍⚕️ Study Director, CSL Behring📍 3 sites📅 Started Feb 2026View details ↗
NARecruitingNCT07461090

Laparoscopic Versus Open Nephrectomy : Clinical Effectivness and Cost Analysis

🏥 Menoufia University📍 1 site📅 Started Feb 2026View details ↗
Phase 3RecruitingNCT06451757

KHENERFIN Study: A Trial to Evaluate the Efficacy and Safety of Sonlicromanol in Primary Mitochondrial Diseases

🏥 Khondrion BV📍 10 sites📅 Started Feb 2026View details ↗
Phase 3RecruitingNCT07390123

Phase Ⅲ Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgAN

🏥 Haisco Pharmaceutical Group Co., Ltd.📍 1 site📅 Started Feb 2026View details ↗
Phase 1RecruitingNCT07270978

Phase Ib Study of CD33 FPBMC in Patients With MRD+ AML or MDS

👨‍⚕️ Daniel Reed, MD, Assistant Professor📍 1 site📅 Started Feb 2026View details ↗
Phase 2RecruitingNCT07356245

Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma

👨‍⚕️ Jonathan Brammer, MD, Ohio State University Comprehensive Cancer Center📍 1 site📅 Started Feb 2026View details ↗
RecruitingNCT07425730

Early Myocardial Dysfunction Helps Identify Severe Refractory Pediatric Lupus

👨‍⚕️ Bao, Shanghai Children's Medical Center, Shanghai Jiaotong University School of Medicine📍 1 site📅 Started Feb 2026View details ↗
NARecruitingNCT07468019

Organization's Unique Protocol ID

🏥 Cairo University📍 1 site📅 Started Feb 2026View details ↗
Phase 3RecruitingNCT06692712

Phase 3 Efficacy Study With Concurrent Control of IT MELPIDA in SPG50.Concurrent Controls.

🏥 Elpida Therapeutics SPC📍 2 sites📅 Started Feb 2026View details ↗
Phase 2RecruitingNCT07419373

ARN-75039 Lassa Fever Treatment in West Africa

👨‍⚕️ Ken McCormack, PhD, Arisan Therapeutics, Inc.📍 4 sites📅 Started Feb 2026View details ↗
← PreviousPage 15 of 478Next →

Get alerts when new trials open

Create a free account to follow conditions and receive trial notifications.

Create free account →